PRINCETON, NJ – May 14, 2019 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical […]
Soligenix, Inc (NASDAQ: SNGX) CEO Dr. Chris Schaber talks about their two Phase III trials and upcoming interim analysis
INTERVIEW HIGHLIGHTS: *Two Pivotal Phase III studies for T-cell Lymphoma and Oral mucositis *Enrollment milestone for SGX942 *Upcoming interim analysis for SGX942 in September *Top-line final results for CTCL expected in 1Q 2020 INTERVIEW SUMMARY: […]
THIS INTERVIEW HAS EXPIRED
THIS INTERVIEW HAS EXPIRED, PLEASE CHECK OUT OUR FEATURED INTERVIEW SECTION FOR OTHER EXCITING OPPORTUNITIES.
Onconova Therapeutics (NASDAQ: ONTX) CEO: Steve Fruchtman THIS INTERVIEW HAS EXPIRED